AUPH
Price
$15.19
Change
-$0.31 (-2.00%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2B
104 days until earnings call
Intraday BUY SELL Signals
JSPR
Price
$1.84
Change
+$0.02 (+1.09%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
51.63M
Intraday BUY SELL Signals
Interact to see
Advertisement

AUPH vs JSPR

Header iconAUPH vs JSPR Comparison
Open Charts AUPH vs JSPRBanner chart's image
Aurinia Pharmaceuticals
Price$15.19
Change-$0.31 (-2.00%)
Volume$18.46K
Capitalization2B
Jasper Therapeutics
Price$1.84
Change+$0.02 (+1.09%)
Volume$5.84K
Capitalization51.63M
AUPH vs JSPR Comparison Chart in %
AUPH
Daily Signal:
Gain/Loss:
JSPR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AUPH vs. JSPR commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Hold and JSPR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (AUPH: $15.20 vs. JSPR: $1.85)
Brand notoriety: AUPH and JSPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 97% vs. JSPR: 66%
Market capitalization -- AUPH: $2B vs. JSPR: $51.63M
AUPH [@Biotechnology] is valued at $2B. JSPR’s [@Biotechnology] market capitalization is $51.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileJSPR’s FA Score has 1 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • JSPR’s FA Score: 1 green, 4 red.
According to our system of comparison, both AUPH and JSPR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 6 TA indicator(s) are bullish while JSPR’s TA Score has 5 bullish TA indicator(s).

  • AUPH’s TA Score: 6 bullish, 4 bearish.
  • JSPR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both AUPH and JSPR are a good buy in the short-term.

Price Growth

AUPH (@Biotechnology) experienced а -2.19% price change this week, while JSPR (@Biotechnology) price change was +4.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

AUPH is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUPH($2B) has a higher market cap than JSPR($51.6M). AUPH YTD gains are higher at: 69.265 vs. JSPR (-91.370). AUPH has higher annual earnings (EBITDA): 86.5M vs. JSPR (-92.73M). AUPH has more cash in the bank: 315M vs. JSPR (39.5M). JSPR has less debt than AUPH: JSPR (2.16M) vs AUPH (81.8M). AUPH has higher revenues than JSPR: AUPH (260M) vs JSPR (0).
AUPHJSPRAUPH / JSPR
Capitalization2B51.6M3,884%
EBITDA86.5M-92.73M-93%
Gain YTD69.265-91.370-76%
P/E Ratio27.14N/A-
Revenue260M0-
Total Cash315M39.5M797%
Total Debt81.8M2.16M3,796%
FUNDAMENTALS RATINGS
AUPH vs JSPR: Fundamental Ratings
AUPH
JSPR
OUTLOOK RATING
1..100
273
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
4999
PRICE GROWTH RATING
1..100
3695
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JSPR's Valuation (37) in the null industry is somewhat better than the same rating for AUPH (74) in the Biotechnology industry. This means that JSPR’s stock grew somewhat faster than AUPH’s over the last 12 months.

AUPH's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as JSPR (100) in the null industry. This means that AUPH’s stock grew similarly to JSPR’s over the last 12 months.

AUPH's SMR Rating (49) in the Biotechnology industry is somewhat better than the same rating for JSPR (99) in the null industry. This means that AUPH’s stock grew somewhat faster than JSPR’s over the last 12 months.

AUPH's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for JSPR (95) in the null industry. This means that AUPH’s stock grew somewhat faster than JSPR’s over the last 12 months.

JSPR's P/E Growth Rating (4) in the null industry is significantly better than the same rating for AUPH (100) in the Biotechnology industry. This means that JSPR’s stock grew significantly faster than AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHJSPR
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AUPH
Daily Signal:
Gain/Loss:
JSPR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LIESX21.64N/A
N/A
Franklin International Equity IS
TRGRX17.42N/A
N/A
T. Rowe Price Global Real Estate
REIPX37.07N/A
N/A
T. Rowe Price Equity Income I
IVNCX23.14-0.01
-0.04%
Macquarie Global Growth Fund Class C
NDVIX17.08-0.03
-0.18%
MFS New Discovery Value I

JSPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, JSPR has been loosely correlated with AUPH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if JSPR jumps, then AUPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JSPR
1D Price
Change %
JSPR100%
+0.82%
AUPH - JSPR
44%
Loosely correlated
-1.94%
ETHZ - JSPR
38%
Loosely correlated
-11.93%
DSGN - JSPR
34%
Loosely correlated
-3.03%
APGE - JSPR
33%
Loosely correlated
-0.02%
PDSB - JSPR
33%
Poorly correlated
-4.93%
More